Viral hepatitis: prognosis and problems


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The problem of viral hepatitis is close to its solution. In 2016 WHO Global Health Sector Strategy for Viral Hepatitis for 2016-2021 has set the task for hepatitis control and elimination, and identified how to address it. The development of such a program has become possible due to the obtained fundamental knowledge about the nature of viral hepatitis, which allows to achieve this ambitious goal. Undoubtedly, the implementation of a program to control viral hepatitis in Russia, based on modern scientific knowledge and the realities of the epidemic process, will make it possible to solve the problem of controlling these diseases. However, new problems arise on this path. This publication addresses some of the current issues, in conjunction with own data. These problems may include: the possibility of the wide spread of hepatitis A virus among certain populations (hepatitis A outbreak in the USA in 2017-2018); the interspecies transmission of HEV from animals to humans; problems encountered in the implementation of the program for mass vaccination against HBV («Vaccine audit»); the history and characteristics of the circulation of the hepatitis D virus in various territories; distribution of circulating forms of the hepatitis C virus with drug resistance to direct-acting drugs (interferon-free therapy). New knowledge on the above mentioned issues are crucial for the successful implementation of the program for the control of viral hepatitis.

全文:

受限制的访问

作者简介

Mikhail Mikhailov

Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: michmich2@yandex.ru
MD; Corresponding Member of the Russian Academy of Sciences; Scientific Director, Institute of Molecular and Personalized Medicine; Department Head, Laboratory of Viral Hepatitis

Karen Kyuregyan

Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: karen-kyuregyan@yandex.ru
BD, Professor of the Russian Academy of Sciences, Head, Department for the Study of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine; Leading Researcher, Laboratory of Viral Hepatitis

Elena Malinnikova

Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: malinacgb@mail.ru
MD, Chief External Expert in Infectious Diseases, Ministry of Health of Russia; Head, Department of Virology; Leading Researcher, Laboratory of Viral Hepatitis

Olga Isaeva

Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: isaeva.06@mail.ru
Cand. Biol. Sci., Leading Researcher, Department for the Study of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine; Leading Researcher, Laboratory of Viral Hepatitis

Anastasiya Karlsen

Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: karlsen12@gmail.com
Researcher, Department for the Study of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine; Researcher, Laboratory of Viral Hepatitis

Ilya Potemkin

Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: axi0ma@mail.ru
Researcher, Department for the Study of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine; Researcher, Laboratory of Viral Hepatitis

Vera Kichatova

Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: vera_kichatova@mail.ru
Researcher, Department for the Study of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine; Researcher, Laboratory of Viral Hepatitis

Abdurakhman Al-Sharabi Shukri

Peoples' Friendship University of Russia

Email: biomedical1999@mail.ru
Shukri, Postgraduate Student, Department of Microbiology

Dmitriy Dogadov

Research Institute of Medical Primatology

Email: dima_loko86@mail.ru
Researcher, Laboratory of Molecular Biology

Lidiya Korzaya

Research Institute of Medical Primatology

Email: likorzaya@rambler.ru
Head, Laboratory of Molecular Biology

Margarita Ignatieva

Federal Service for Supervision of Consumer Rights Protection and Human Well-Being Directorate for the Republic of Sakha (Yakutia)

Email: akutia@14.rospotrebnadzor.ru
Cand. Med. Sci., Head

Andrey Polyakov

Skolkovo Territorial Department of the Federal Service for Supervision of Consumer Rights Protection and Human Well-Being Directorate for the City of Moscow

Email: postoscol@mail.ru
Cand. Med. Sci., Head

参考

  1. Lemon S.M., Ott J.J., van Damme P., Shouval D. Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J. Hepatol. 2017; 68 (1): 167-84.
  2. Foster M., Ramachandran S., Myatt K., Donovan D., Bohm S., Fiedler J. et al. Hepatitis A Virus Outbreaks Associated with Drug Use and Homelessness - California, Kentucky, Michigan and Utah, 2017. MMWR Morb Mortal Wkly Rep. 2018; 67(43): 1208-10. D0I:10.15585/mmwr.mm6743a3
  3. Паршли Л., Мойер М.У Новые болезни нового мира. В мире науки 2018; (7): 54- 69.
  4. Smith D.B., Simmonds Р., Jameel S. Consensus proposals for classification of the family Hepeviridae. J. Gen. Virol. 2014; 95: 2223-32.
  5. Woo P.C.Y., Lau S.K.P., Teng L.L., Cao K.Y., Wernery U., Schountz, T. et al. New Hepatitis E Virus Genotype in Bactrian Camels, Xinjiang, China, 2013. Emerg. Infect. Dis. 2016; 22(12): 2219-21.
  6. Teshale E.H., Hu D.J., Holmberg S.D. The two faces of hepatitis E virus. Clin. Infect. Dis. 2010; 51: 328-34.
  7. Михайлов М.И., Малинникова Е.Ю., Кюрегян К.К., Исаева О.В. Случай завоза вируса гепатита Е 4 генотипа в Россию. Журнал микробиологии, эпидемиологии и иммунобиологии 2016; (3): 64-9.
  8. Mохаммед А.М.Е., Потемкин И.А., Карлсен А.А., Исаева О.В., Кюрегян К.К., Козлов В.Г., Жаворонок С.В., Михайлов М.И. Циркуляция вируса гепатита Е кроликов на территориях с разной степенью эндемичности по гепатиту Е. Современные проблемы науки и образования 2015; (2). https://science-education.ru/ru/article/ view?id=18395
  9. Кожанова Т.В., Клушкина В.В., Гордейчук И.В., Кюрегян К.К., Михайлов М.И. Оценка иммунологической эффективности массовой вакцинации против гепатита В. Труды Института полиомиелита и вирусных энцефалитов имени М.П. Чумакова РАМН. Медицинская вирусология 2014; 28(1): 16-25.
  10. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 2018. pii. S0168-8278(18)31968-8. doi: 10.1016/j.jhep.2018.03.026.
  11. Vermehren J., Susser S., Dietz.J., von Hahn T., Petersen J., Hinrichsen H. Retreatment of patients who failed DAA-combination therapies: real-world experience from a large hepatitis C resistance database. J. Hepatol. 2016; 64 (2): S188. DOI: https:// doi.org/10.1016/S0168-8278(16)00128-8.
  12. Wyles D.L. Resistance to DAAs: When to Look and When It Matters. Curr. HIV/AIDS Rep. 2017; 14(6): 229-37. DOI: 10.1007/ s11904-017-0369-5.
  13. Wyles D., Mangia A., Cheng W., Shafran S., Schwabe C., Ouyang W. Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Antivir. Ther. 2017; 23(3):229-238. doi: 10.3851/IMP3181.
  14. Abravanel F., Motivier S., Chauveau M., P6ron J.-M., Izopet J. et al. Transmission of HCV NS5A Inhibitor-Resistant Variants Among HIV-Infected Men Who Have Sex With Men. Clin. Infect. Dis. 2016; 63(9): 1271-2.
  15. Никитин И.Г., Попович Л.Д., Потапчик Е.Г. Экономическое бремя хронического гепатита С в России. Эпидемиол. инфекц. болезни. Актуал. вопр. 2015; (6): 9-13.
  16. Исаева О.В., Кичатова В.С., Карлсен А.А., Солонин С.А., Дмитриев П.Н., Кюрегян К.К., Михайлов М.И. Многолетняя динамика распространения генотипов вируса гепатита С в Московском регионе. Журнал микробиологии, эпидемиологии и иммунобиологии 2016; (4): 35-42.
  17. Кичатова В.С., Карлсен А.А., Исаева О.В., Солонин С.А., Малинникова Е.Ю., Кюрегян К.К., Михайлов М.И. Лекарственно-резистентные варианты ВГС субитпа 1b, циркулирующие на территории Российской Федерации: анализ аминокислотных мутаций в белках NS5a и core. Журнал инфектологии 2018; 10(4): 30-6. doi: 10.22625/2072-6732-2018-10-4 30-36.
  18. Jacobson I.M., Asante-Appiah E., Wong P., Black T., Howe A.Y.M. Prevalence and impact of baseline NS5A resistance associated variants (RAVs) on the efficacy of elbasvir/ grazoprevir (EBR/GZR) against GT1a infection. Hepatol. Baltim. Md. 2015; 62: 1393A-4A.
  19. Zeuzem S., Mizokami M., Pianko S., Mangia A, Han KH, Martin R. et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. J. Hepatol. 2017; 66(5): 910-8.
  20. Recommendations for Testing, Managing, and Treating Hepatitis C/HCV Guidance. http://hcvguidelines.org/.
  21. Михайлов М.И., Ющук Н.Д., Проект программы по контролю и ликвидации вирусных гепатитов как проблемы общественного здравоохранения. Медицинская газета 2018; (11): 10-1.
  22. Михайлов М.И., Ющук Н.Д., Малинникова Е.Ю., Кюрегян К.К., Исаева О.В., Знойко О.О., Климова Е.А. Проект программы по контролю и ликвидации вирусных гепатитов как проблемы общественного здоровья в Российской Федерации. Инфекционные болезни: новости, мнения, обучение 2018; 7(2): 52-8.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2019
##common.cookie##